Registration Number
0220U102620,
0118U003731
, R & D reports
Title
Improve the treatment of primary lymphoma patients with B cellular origin
popup.stage_title
Head
Kriachok Iryna A,
Registration Date
10-04-2020
Organization
National Cancer Institute
popup.description2
A statistically significant difference in the level of GVR in patients with LH with different Deauville 5-PS parameters was found when evaluating PET-2. Three-year BWF in patients with PET-2 according to the Deauville1–2 scale compared to 4–5 points in Deauville was 90.7% versus 46.3%, respectively (P <0.004). The level of 3-year HBV in patients with PET-2 Deauville 3 versus Deauville 4–5 was 85.7% versus 46.3%, respectively (P <0.05). In multivariable analysis, no statistically significant correlation was found between PET-2 + and extranodal lesions or high tumor mass. 88.8% (79/89) and 11.2% (10/89) of patients in the study group had PET-3- negative (PET-3-) and positive (PET-3 +), respectively (p <0 , 05). Most patients with early and late stages of the disease achieved complete remission (PET-3 negative (95.7% and 80%, respectively), but found 20% versus 4.2% of patients who had PET-3 + with III- Stages IV and I-II, respectively (p <0.05) The 1-year BIR was 100% versus 50% for patients who had PET-3 (IPS0-2) -negative against PET-3 (IPS0-2) ) -positive and 87% against 30% PET-3 (IPS3) -negative against PET-3 (IPS3) - positive respectively (log test, p <0.0001) .The mean follow-up time was 18.3 months, 3- the annual rate of RV and RV for all patients was 85% and 97% respectively, 5-year BIR and SV indicators 82% and 97% respectively (p = 0.004) The advantages of R-DA-EPOCH treatment were found in evaluating the effectiveness of treatment in patients with DVLL from the adverse prognosis group. , a positive response to therapy was achieved in 96.3% of patients in group III versus 73.6 and 81.7% of patients in group I and II, respectively (p = 0.047), and 85.2% of patients in group III against 41.5% and 60.0% of patients in the I and II groups, respectively (p = 0.005). Similar results were obtained for patients under 60 years of age. The 2-year SV in group III was (91.2 ± 6.0)% versus (56.7 ± 7.8)% in group I and (67.7 ± 6.6)% in group II of patients (p = 0,043).
Product Description
popup.authors
Aleksyk Olena M
Martynchyk Arina V
Titorenko Iryna B
popup.nrat_date
2020-07-03
